The ODYSSEY Outcomes (ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) study showed that alirocumab reduced the concentration of Lp(a) by 23%. This evidence concerns the gene LPA and acute coronary syndrome.